(TEVA) Teva Pharma Industries - Ratings and Ratios

Exchange: NYSE • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098

TEVA: Generic, Medicines, Biopharmaceuticals, CNS, Respiratory, Oncology

Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) is a global leader in the development, production, and distribution of generic and specialty medicines, operating across 60 countries with a workforce of over 40,000. The company specializes in high-quality, affordable healthcare solutions, focusing on central nervous system (CNS) disorders, respiratory conditions, and oncology. Its product portfolio includes complex generics such as injectables, inhalants, and biosimilars, alongside innovative treatments like AJOVY for migraines and COPAXONE for multiple sclerosis. Teva also offers over-the-counter (OTC) products and active pharmaceutical ingredients (APIs), serving as a key supplier to the pharmaceutical industry. The company emphasizes sustainability and innovation, investing in digital health solutions and green manufacturing processes to reduce its environmental impact. Tevas strategic collaborations with biotech firms and research institutions underscore its commitment to advancing healthcare access and affordability worldwide.

3-Month Forecast: Based on and , Tevas stock is expected to face short-term volatility. The SMA 20 (14.31) and SMA 50 (15.51) suggest potential resistance levels, while the ATR (0.71) indicates moderate price fluctuations. With a forward P/E of 5.26, the stock may attract value investors despite the negative RoE (-30.45). However, the companys debt levels and restructuring efforts could impact near-term performance. The outlook remains neutral, with potential upside driven by cost-cutting measures and new product launches, but downside risks include pricing pressures in the generics market and regulatory challenges.

Additional Sources for TEVA Stock

TEVA Stock Overview

Market Cap in USD 19,418m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 1990-03-26

TEVA Stock Ratings

Growth Rating 20.6
Fundamental -11.7
Dividend Rating 18.1
Rel. Strength 12.2
Analysts 4.4/5
Fair Price Momentum 16.03 USD
Fair Price DCF 20.24 USD

TEVA Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 72.3%

TEVA Growth Ratios

Growth Correlation 3m -11.1%
Growth Correlation 12m -23.2%
Growth Correlation 5y 42.1%
CAGR 5y 7.54%
CAGR/Max DD 5y 0.16
Sharpe Ratio 12m -0.39
Alpha -4.75
Beta 0.465
Volatility 50.46%
Current Volume 8586.6k
Average Volume 20d 12032.4k
What is the price of TEVA stocks?
As of May 17, 2025, the stock is trading at USD 16.94 with a total of 8,586,595 shares traded.
Over the past week, the price has changed by +0.06%, over one month by +26.14%, over three months by +2.23% and over the past year by +3.93%.
Is Teva Pharma Industries a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Teva Pharma Industries is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.72 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TEVA as of May 2025 is 16.03. This means that TEVA is currently overvalued and has a potential downside of -5.37%.
Is TEVA a buy, sell or hold?
Teva Pharma Industries has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy TEVA.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for TEVA stock price target?
According to ValueRays Forecast Model, TEVA Teva Pharma Industries will be worth about 17.3 in May 2026. The stock is currently trading at 16.94. This means that the stock has a potential upside of +2.36%.
Issuer Forecast Upside
Wallstreet Target Price 22.6 33.6%
Analysts Target Price 22.4 32.1%
ValueRay Target Price 17.3 2.4%